Europe’s medicine shortages stem from pricing policies and fragile supply chains that prioritize low costs over reliability. These shortages threaten patient safety, increase healthcare costs, and deepen inequalities. Stronger procurement policies, diversified suppliers, coordinated stockpiling, and improved monitoring are essential to ensuring a resilient medicine supply.

Generative AI can reduce clinical documentation burdens and improve communication efficiency, but its use introduces risks involving inaccurate outputs, automation bias, privacy, liability, and patient trust. Safe deployment requires mandatory human verification, transparent patient disclosure, strong data protections, and continuous auditing to ensure efficiency gains do not compromise clinical quality or safety

Rising public debt is intensifying fiscal pressure across France and other advanced economies, but cancelling government bonds held by central banks offers no genuine economic relief. Such cancellation largely shifts liabilities within the public sector while potentially undermining market credibility and raising borrowing costs. Sustainable debt management ultimately depends on stronger growth, credible deficit reduction, and effective burden-sharing rather than accounting s

Clinical AI can improve diagnostic speed, efficiency, and patient care, but it must remain subordinate to human clinical judgment. A robust Human-in-the-Loop framework requires physician accountability, patient transparency, data protection, continuous algorithmic auditing, and measures to prevent automation bias and clinician deskilling.

NBA evidence challenges common assumptions about talent management: top performers do not necessarily become strong leaders, high status can reduce the additional rewards of success, and recent success may even weaken subsequent performance. Organizations should therefore evaluate employees based on future role requirements, actual contribution, and sustained evidence rather than relying on reputation or past results. Article 024

Managers often judge foreign markets not by actual institutional differences, but by how different or familiar those markets appear. Underestimating differences can encourage poorly prepared expansion, while exaggerating them can cause firms to reject viable opportunities. Better decisions require cognitive flexibility, systematic evidence, and treating familiarity as a hypothesis rather than a fact.